SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)
RIGL 36.60-3.4%12:43 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (243)3/28/2005 4:45:03 PM
From: keokalani'nui   of 566
 
I never dumped it all and now I've added enough RIGL to start paying attention again, though not a full position. Hopefully this time I'll make money.

I was seeking a reality check on the R112 results since clearly RIGL thinks the rhinitis program is worth more than PFE, disconcerting since PFE is known to open its pocketbook wide when the drug is good. So I was pleasantly surprised to see how weak the Allegra registration studies were, and so I've decided that although the R112 9% RR vs plo looked modest, the 38% reduction from baseline certainly was not. As well the relatively rapid onset of 30 min would be a big improvement over anything else. A little worried that the co didn't mention other specific symptom scores, sneezing, itchy eyes...has anybody seen a more complete data presentation?

Will be interesting to see how the corticosteroid trial is run. A 5-day trial with simultaneous dosing days 1-5? <g>

Also, can't resist the romance of the novel syk for RA, the aurora kinase and UL cancer candidates...all poised for meaningful introductions this year. And, with best of luck, there is a quick fix to hcv.

Wish it was selling at a distressed price, but in a diversified portfolio there is a place for rigl now.

IMO!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News